Protection of the Heart With Remote Ischemic Preconditioning During Heart Surgery: A Pilot Study
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Purpose:
- Determine, in a pilot study, if surrogate markers of rIP can be detected in patients presenting for cardiac surgery. Specifically measure the effect of rIP on the expression profile of HSP-70, iNOS, PKC-E, p38 MAPK, PI3K, and sarcolemmal KATP
- Determine if rIP influences the expression of genes known to influence substrate preference and thereby myocardial metabolism in patients undergoing heart surgery. Specifically the expression of HIF-1a, PPAR-a and AMPK
Hypothesis:
We hypothesize that rIP provides myocardial protection in patients presenting for heart surgery and that this protection is defined by a distinct gene expression profile with regards to genes involved in rIP and myocardial metabolism.
Study Design:
This proposal is for a randomized blinded pilot study on the use of rIP in patients requiring heart surgery.
Study Population:
The study will include 100 male and female patients undergoing elective heart surgery with cardiopulmonary bypass (CPB).
Randomization:
Patients will be randomized 1:1 to receive either rIP or no treatment.
Blinding Procedures:
The patient will be blinded as well as those performing the experimental analysis.
Interventions:
Remote Ischemic Preconditioning
rIP will be induced immediately following induction of anesthesia. Four 5 minute cycles of lower unilateral limb ischemia and reperfusion induced tourniquet inflation to 300 mmHg will constitute the preconditioning stimulus.
Blood sample collection/analysis
- Two cardiac biopsies (50 - 200 mg) will be collected pre-bypass and post- bypass and will be analyzed for gene and protein expression.
- Blood samples (4 mL) will be drawn immediately before induction of anesthesia, and at the same times as cardiac tissue samples are harvested and analyzed for gene/protein expression as well as at 1, 24, 48 and 72 hours post surgery. Troponin I and NT-ProBNP will be measured at baseline, 1, 24, 48 and 72 hours after surgery and 3 mL of blood will be collected for these tests. A total of 43 mL of blood will be collected per patient.
- rIP induced changes in leukocyte gene expression will be measured at the aforementioned time points.
Other
ECG assessment on post-operative day 1, 2, and 3.
National Institute of Health stroke scale assessment will be conducted at screening and post operatively prior to hospital discharge.
Each patient will receive a telephone follow-up call at 30 days post operatively to collect adverse events and mortality data.
Experimental Methods:
- qRT-PCR will be used to measure gene expression.
- Immunoblotting will be used to measure protein expression
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2G3
- University of Alberta
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Written informed consent
- Age 18 through 80 years, inclusive
- Scheduled for heart surgery with CPB
Exclusion Criteria:
- Females of childbearing potential
- Emergency surgery
- Previous sternotomy
- Myocardial infarction within 48 hours prior to surgery
- Diabetes and/or BMI >35
- Need for Alpha2-agonists perioperatively
- Peripheral Vascular Disease
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Ischemic Preconditioned Group (rIP)
A 15-cm sterile blood pressure cuff was placed around the right thigh and connected to the inflating device, and the patient was draped obscuring the visibility of the cuff.
Subsequently, the patient was randomly allocated (by opening of an envelope) to RIPC consisting of four 5-min cycles of lower limb ischemia-reperfusion induced by a tourniquet inflated to 300 mmHg
|
The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes.
This will be done 4 times in a row.
|
|
Aucune intervention: No Cuff
No rIP
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Myocardial Protection Against Ischemic Injury
Délai: 72 hours post operatively
|
High-sensitivity cardiac troponin T release as measured by peak hscTnT values and area-under-the-curve.
|
72 hours post operatively
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
All-cause Death and Cardiovascular Long-term Outcome
Délai: 6-month cardiovascular outcome
|
Death and re-hospitalization due to any cause including heart and renal failure and new atrial fibrillation
|
6-month cardiovascular outcome
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Barry A Finegan, MB, University of Alberta
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- PROTECT
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .